Showing results (11-20 of 23) with videos related to

Sort By:
Pageof 3
Clinical Colorectal Cancer|May 27, 2008
Pathologic complete response to neoadjuvant FOLFOX in combination with bevacizumab in unresectable metastatic colorectal carcinomaAustin Duffy, Jinru Shia, Fidel David Huitzil-Melendez, et al.
Surgical Oncology Clinics of North America|March 25, 2009
Indications for neoadjuvant, adjuvant, and palliative chemotherapy in the treatment of biliary tract cancersFidel David Huitzil-Melendez, Eileen M O'Reilly, Austin Duffy, et al.
United European Gastroenterology Journal|June 12, 2014
Fibrolamellar hepatocellular carcinoma in the USA, 2000-2010: A detailed report on frequency, treatment and outcome based on the Surveillance, Epidemiology, and End Results databaseTobias Eggert, Katherine A McGlynn, Austin Duffy, et al.
Immunology|February 7, 2012
S100A9 a new marker for monocytic human myeloid-derived suppressor cellsFei Zhao, Bastian Hoechst, Austin Duffy, et al.
Cancer Immunology, Immunotherapy : CII|February 15, 2002
Generation of activated and antigen-specific T cells with cytotoxic activity after co-culture with dendritic cellsAngela Märten, Tim Greten, Carsten Ziske, et al.
BJR Case Reports|September 14, 2022
Enhanced toxicity to chemoradiation in a patient with Anti-Jo-1-antisynthetase syndromeLuca Valle, James Katz, Austin Duffy, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 12, 2010
Advanced hepatocellular carcinoma: which staging systems best predict prognosis?Fidel-David Huitzil-Melendez, Marinela Capanu, Eileen M O'Reilly, et al.
Cancer Immunology, Immunotherapy : CII|September 27, 2012
Comparative analysis of monocytic and granulocytic myeloid-derived suppressor cell subsets in patients with gastrointestinal malignanciesAustin Duffy, Fei Zhao, Lydia Haile, et al.
Journal of Vascular and Interventional Radiology : JVIR|December 12, 2018
Pilot Study Comparing Systemic and Tissue Pharmacokinetics of Irinotecan and Metabolites after Hepatic Drug-Eluting ChemoembolizationElliot B Levy, Cody Peer, Tristan M Sissung, et al.
Investigational New Drugs|December 16, 2015
A phase I study of selumetinib (AZD6244/ARRY-142866), a MEK1/2 inhibitor, in combination with cetuximab in refractory solid tumors and KRAS mutant colorectal cancerDustin A Deming, Ludmila L Cavalcante, Sam J Lubner, et al.
Pageof 3